SynthesisJournal of human hypertension2026
Prognostic value of blood pressure variability in patients with heart failure: a systematic review and meta-analysis.
Synthesis in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood pressure variability (BPV) has been associated with increased morbidity and mortality across various cardiovascular conditions, but its prognostic significance in heart failure (HF) remains insufficiently established. This review aims to assess the potential utility of BPV as a prognostic marker in the HF population. We conducted a systematic review and meta-analysis of 15 studies including 33,022 patients (mean age 66.2 ± 10.5 years). Composite endpoints included all-cause mortality, cardiovascular mortality, HF rehospitalization, nonfatal stroke, nonfatal myocardial infarction, and heart transplantation. Pooled hazard ratios were calculated using a generic inverse variance approach under a random-effects model. Higher long-term BPV was significantly associated with increased risk of composite outcomes (HR 1.20, 95% CI 1.01-1.43; I² = 89%, p = 0.03) and all-cause mortality (HR 1.15, 95% CI 1.05-1.25; I² = 49%, p = 0.001). Daytime short-term BPV showed an inverse association (OR 0.96, 95% CI 0.92-0.99; I² = 0%, p = 0.01), while a U-shaped relationship between long-term BPV and risk of composite outcomes and cardiovascular mortality was observed. These findings suggest that BPV may serve as a prognostic factor for secondary risk stratification in patients with HF.
Indexed as
Identifiers
41917552What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.